Would you offer local therapy with either SBRT or Y-90 in a patient with metastatic ER+ HER2 low breast cancer with two oligometastatic liver lesions currently on AI + CDK4/6 inhibitor?

No.

Longer answer:

I acknowledge that controlling liver disease improves outcomes in metastatic cancer (including breast, and including y-90 for breast Barakat et al., PMID 35071835). However, it depends on how and when you use the tool. My reason for saying no in this setting: this is a patient with ...